Trial Profile
Phase I Study Evaluating MK6592 in Combination With Docetaxel in Adult Patients With Relapsed or Refractory Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs MK 6592 (Primary) ; Antineoplastics; Docetaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck & Co
- 13 Nov 2007 Status changed from recruiting to discontinued
- 08 Nov 2006 New trial record.